chufangao/CTO huggingface dataset:
Clinical trial NCT03679845: Study to Assess Sarilumab in Halting Progression of Morphea
Official title: A Pilot Study to Assess the Safety and Efficacy of Sarilumab in Halting Progression of Morphea
Sponsor: Massachusetts General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Difficulty in recruiting patients
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-09-01
Primary completion date: 2021-06-30
Completion date: 2021-06-30
Plan to share individual participant data: NO
Clinical trial NCT05275907: Mechanism of Hypertension Treatments in Liver Transplant Recipients (BLOCK LTR-HTN)
Official title: Pilot Study to Assess Blockade of Calcium Channels and Sodium Chloride Cotransporters for Physiologic Abnormalities in Liver Transplant Associated Hypertension
Sponsor: Northwestern University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Screened participants did not meet inclusion criteria prior to study completion date
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-07-12
Primary completion date: 2023-10-02
Completion date: 2023-10-04
Plan to share individual participant data: YES
IPD sharing description: Individual participant data that underlie the results reported, after deidentification
IPD time frame: Following publication with no end date.
IPD access criteria: Any purpose.
Clinical trial NCT04505098: A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults
Official title: A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults (MITIGATE)
Acronym: MITIGATE
Sponsor: Kaiser Permanente (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: The study was suspended by the IRB of record and subsequently terminated
Enrollment: 39600.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-07
Primary completion date: 2022-12-15
Completion date: 2022-12-15
Plan to share individual participant data: NO
Clinical trial NCT05022797: Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS
Official title: Reduction of MTX Levels After Treatment With Reduced Glucarpidase Dose in Patients With DLBCL at Risk of CNS Involvement Who Receive Cycles of HDMTX: an Open-label, Interventional, Non-randomized, Phase 2, Pilot, Multicenter Study
Sponsor: Fundacion CRIS de Investigación para Vencer el Cáncer (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: closed because of low recruitment
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-07-19
Primary completion date: 2022-11-22
Completion date: 2022-11-22
Plan to share individual participant data: NO
Clinical trial NCT04957914: A Study of LY3209590 on Low Blood Sugar in Participants With Type 2 Diabetes Mellitus
Official title: Effects of LY3209590 on Frequency and Severity of Hypoglycaemia Under Conditions of Increased Hypoglycaemic Risk Compared to Insulin Glargine in Participants With Type 2 Diabetes Mellitus
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 54.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-07-14
Primary completion date: 2022-10-17
Completion date: 2022-10-17
Plan to share individual participant data: NO
Clinical trial NCT01910402: A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)
Official title: A Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine Once Daily Compared to Atazanavir and Ritonavir Plus Tenofovir/Emtricitabine Once Daily in HIV-1 Infected Antiretroviral Therapy Naïve Women
Sponsor: ViiV Healthcare (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 499.0 (ACTUAL)
Number of arms: 2.0
Start date: 2013-08-22
Primary completion date: 2015-09-22
Completion date: 2022-08-18
Baseline population: Baseline Characteristic data are reported for members of the ITT-E Population which comprised of all randomized participants who received at least one dose of study treatment.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on ViiV's data sharing criteria can be found at: https://viivhealthcare.com/about-viiv/corporate-ethics-compliance/commitment-to-data-transparency/
IPD time frame: Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
IPD access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Clinical trial NCT05188664: Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors
Official title: A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM- 302 in Combination With Toripalimab in Patients With Advanced Solid Tumors
Sponsor: LaNova Medicines Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Sponsor's decision
Enrollment: 20.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-05-10
Primary completion date: 2023-11-14
Completion date: 2023-11-14
Plan to share individual participant data: NO
Clinical trial NCT03571204: Combination Therapy With 3BNC117 and 10-1074 in HIV-Infected Individuals
Official title: An Exploratory Study of Combination Therapy With 3BNC117 and 10-1074 in HIV-Infected Individuals
Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Coronavirus 2019 (COVID-19) pandemic
Enrollment: 27.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-09-10
Primary completion date: 2021-03-29
Completion date: 2021-03-29
Baseline population: Group 2 ART naiive
Limitations and caveats: The study was terminated early due the the COVID-19 pandemic. The pre-defined samples size of 30 participants (15 per arm) for Group 1 was not not reached prior to closing the protocol.
Clinical trial NCT06115460: The Impact of Sitagliptin as an Add on Therapy With Closed Loop Control in Adolescents With Diabetic Nephropathy
Official title: The Impact of Sitagliptin as an Add on Therapy With Closed Loop Control in Adolescents With Type 1 Diabetes Mellitus and Diabetic Nephropathy
Sponsor: Ain Shams University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 46.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-03-01
Primary completion date: 2023-06-01
Completion date: 2023-06-15
Plan to share individual participant data: UNDECIDED
IPD sharing description: All data are available upon request
Clinical trial NCT01965704: Can Ondansetron Prevent Neonatal Abstinence Syndrome (NAS) in Babies Born to Narcotic-dependent Women
Official title: AIM 2- Prevention of Neonatal Abstinence Syndrome
Acronym: AIM2NAS
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 196.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-09-09
Primary completion date: 2020-09-03
Completion date: 2020-09-16
Baseline population: Participants who completed the protocol and met all inclusion criteria are included in the analysis.
Plan to share individual participant data: NO
IPD sharing description: We will not share any individual participant data with other researchers.
Clinical trial NCT03623568: Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant
Official title: Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant
Sponsor: Massachusetts General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: did not move forward with IRB approval, competing study
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-02-15
Primary completion date: 2020-12-31
Completion date: 2021-04-15
Plan to share individual participant data: YES
IPD sharing description: Anticipate to share coded data with collaborators
IPD time frame: Anticipate data would be available to share within 6 months after the final patient completes the study.
IPD access criteria: Coded data would be shared with collaborators who have received IRB approval to use the data and have been approved by the PI for their collaboration.
Clinical trial NCT04830735: Dasatinib for the Treatment of Moderate and Severe COVID-19
Official title: A Phase II Randomized Double-Blind Trial of Dasatinib Modulation of Hyperinflammation in Moderate and Severe Patients With COVID-19
Sponsor: University of Southern California (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: PI decided not to pursue study
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-08-05
Primary completion date: 2023-12-15
Completion date: 2024-12-15
Clinical trial NCT04858425: Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection
Official title: A 2-Part, 2-Arm, Phase 2, Randomized, Double-Blind, Placebo-Controlled Study on the Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection
Acronym: RESERVOIR
Sponsor: Entero Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The termination of the study was a decision based on topline data analysis (no efficacy as per Day 43) of the study data.
Enrollment: 166.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-30
Primary completion date: 2022-06-04
Completion date: 2023-09-10
Plan to share individual participant data: NO
Clinical trial NCT04083651: A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer
Official title: A Phase II/III Adaptive Study to Evaluate the Safety and Efficacy of Oral Methylnaltrexone Bromide Tablets in Subjects With Advanced Pancreatic Cancer
Sponsor: Bausch Health Americas, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: Due to pandemic challenges and consideration of a different study design in the future.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-06
Primary completion date: 2023-10-15
Completion date: 2023-10-15
Clinical trial NCT02775435: A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)
Official title: A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407)
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 559.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-06-09
Primary completion date: 2018-04-03
Completion date: 2023-09-14
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT02920190: Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat
Official title: Reduction of Antigen-Lipid-Driven Monoclonal Gammopathies by Targeting Epicardial Fat and Its Lipids Content With Liraglutide: A Glucagon Like Peptide-1 Receptor Analogue (GLP-1RA)
Sponsor: University of Miami (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Lack of funds to cover the costs of the study medications
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-09-01
Primary completion date: 2021-09-01
Completion date: 2021-12-31
Plan to share individual participant data: NO
Clinical trial NCT05011019: A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis
Official title: Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis (Neurofibromatosis and Malignant Peripheral Nerve Sheath Tumors)
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: sponsor adjusts its research and development strategy
Enrollment: 22.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-09-07
Primary completion date: 2024-02-02
Completion date: 2024-02-02
Clinical trial NCT02913261: Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation
Official title: A Phase III Randomized Open-label Multi-center Study of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation
Acronym: REACH2
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 310.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-03-10
Primary completion date: 2019-06-24
Completion date: 2021-04-23
Baseline population: Full Analysis Set (FAS): The Full Analysis Set (FAS) comprised all patients to whom study treatment was assigned by randomization.
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT03923257: Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents
Official title: Phase I Trial of Peptide Receptor Radiotherapy (PRRT) With 177Lu-DOTA-tyr3-Octreotate (177Lu-DOTATATE) in Children and Adolescents With Neuroendocrine Tumor or Pheochromocytoma/Paraganglioma
Sponsor: University of Iowa (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: competing clinical trial opening
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-08-04
Primary completion date: 2021-06-03
Completion date: 2021-06-03
Plan to share individual participant data: NO
Clinical trial NCT05077930: Convalescent Plasma Therapy for Hospitalized Patients With COVID-19
Official title: Validation Protocol for The Clinical Use of Convalescent Plasma for Hospitalized Patients With COVID-19. A Prospective Study at a Hospital in Southern Brazil.
Sponsor: Science Valley Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 38.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-01-06
Primary completion date: 2022-04-04
Completion date: 2022-04-07
Plan to share individual participant data: UNDECIDED
Clinical trial NCT05051579: A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities
Official title: A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 272.0 (ACTUAL)
Number of arms: 7.0
Start date: 2021-09-29
Primary completion date: 2022-08-25
Completion date: 2022-11-22
Baseline population: All randomized participants.
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT04774809: Assess the Efficacy and Safety of SHR0302 Ointment in Adult Patients With Vitiligo
Official title: A Randomized, Double-blind, Vehicle-Controlled, Phase II/Ⅲ Seamless Adaptive Clinical Trail to Evaluate the Efficacy and Safety of SHR0302 Ointment in Adult Patients With Vitiligo
Sponsor: Reistone Biopharma Company Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: terminated by sponsor
Enrollment: 75.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-01-29
Primary completion date: 2022-03-21
Completion date: 2022-03-21
Plan to share individual participant data: NO
Clinical trial NCT04711863: Fluvoxamine for Adults With Mild to Moderate COVID-19
Official title: Fluvoxamine for Adults With Mild to Moderate COVID-19: A Single-blind, Randomized, Placebo-controlled Trial
Sponsor: Asan Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: SUSPENDED 
Why stopped: Closure of main community treatment center
Enrollment: 400.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2021-01-16
Primary completion date: 2021-05-31
Completion date: 2021-07-31
Plan to share individual participant data: NO
Clinical trial NCT04168957: An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007
Official title: An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007
Sponsor: Athenex, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: No need to complete the overall survival (OS) follow-up as the sample size was too small to interpret OS.
Enrollment: 11.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-10-25
Primary completion date: 2019-08-27
Completion date: 2020-11-12
Plan to share individual participant data: UNDECIDED
Clinical trial NCT01700569: Phase-1 Study of Folinic Acid to Modulate MGMT Gene in Glioblastoma
Official title: Phase I Study of Escalated Pharmacologic Dose, of Oral Folinic Acid in Combination With Temozolomide, According to Stupp R. Regimen, in Patients With Operated Grade-IV Astocytoma and a Non-methylated Gene Status of MGMT.
Acronym: FOLAGLI
Sponsor: Institut Cancerologie de l'Ouest (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: changing the standard of care
Enrollment: 24.0 (ACTUAL)
Number of arms: 1.0
Start date: 2013-01-31
Primary completion date: 2019-12-12
Completion date: 2021-04-16
Clinical trial NCT02919436: Decreasing Rates of Intraurethral Catheterization Postoperatively in Spine Surgery
Official title: Decreasing Rates of Intraurethral Catheterization Postoperatively in Spine Surgery
Acronym: DRIPS
Sponsor: MaineHealth (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 610.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-03-31
Primary completion date: 2020-01-31
Completion date: 2020-11-30
Plan to share individual participant data: NO
Clinical trial NCT03880474: Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults
Official title: A Phase 2b Study to Determine the Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults Aged 18 Years and Over
Sponsor: Barinthus Biotherapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The trial is being stopped for futility. Season 2 cancelled.
Enrollment: 2364.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-03-18
Primary completion date: 2019-10-15
Completion date: 2020-01-21
Plan to share individual participant data: NO
Clinical trial NCT04596293: Efficacy and Safety of Orally Administered BBT-401-1S in Subjects With Ulcerative Colitis
Official title: A Randomised, Double-blind, Placebo-controlled Study of Orally Administered BBT-401-1S in Subjects With Moderate to Severe Ulcerative Colitis, Incorporating a Response-adaptive, Double-blind Extension Phase
Sponsor: Bridge Biotherapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 38.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-06-11
Primary completion date: 2022-05-17
Completion date: 2022-07-12
Clinical trial NCT04816214: Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy
Official title: A Phase III Randomized, Controlled, Open-label, Multicenter, Global Study of Capmatinib in Combination With Osimertinib Versus Platinum - Pemetrexed Based Doublet Chemotherapy in Patients With Locally Advanced or Metastatic NSCLC Harboring EGFR Activating Mutations Who Have Progressed on Prior Generation EGFR-TKI Therapy and Whose Tumors Are T790M Mutation Negative and Harbor MET Amplification (GEOMETRY-E)
Acronym: GEOMETRY-E
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Novartis decided to terminate the study based on a business consideration and not related with any safety concerns. Randomized part was not initiated
Enrollment: 6.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-09-22
Primary completion date: 2022-12-27
Completion date: 2022-12-27
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Clinical trial NCT03347123: A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)
Official title: A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208)
Sponsor: Incyte Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: A business decision made by Incyte after analysis of data from a sister study.
Enrollment: 11.0 (ACTUAL)
Number of arms: 7.0
Start date: 2018-03-21
Primary completion date: 2021-01-29
Completion date: 2021-01-29
Baseline population: Full analysis set included all participants enrolled in the study who received at least 1 dose of combination therapy.
Plan to share individual participant data: NO
Clinical trial NCT04937738: Perioperative Chemotherapy in Gastric Cancer
Official title: Treatment Discontinuation Associated With Perioperative Toxicity of FLOT Versus XELOX Chemotherapy in Patient With Resectable Gastric Cancer; Phase 2
Acronym: PECORINO
Sponsor: Ukrainian Society of Clinical Oncology (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: High rate of disease progression in XELOX arm
Enrollment: 69.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-07-21
Primary completion date: 2023-02-01
Completion date: 2023-02-01
Plan to share individual participant data: YES
IPD sharing description: After the initial publication every participant will recieve all the data to provide further data exploration.
IPD time frame: Data will be available after initial paper is published.
IPD access criteria: By request